120 related articles for article (PubMed ID: 37784256)
41. Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT.
Baron F; Ruggeri A; Peczynski C; Labopin M; Bourhis JH; Michallet M; Chevallier P; Sanz J; Forcade E; Saccardi R; Potter V; Gluckman E; Nagler A; Mohty M
Bone Marrow Transplant; 2023 Aug; 58(8):936-941. PubMed ID: 37165084
[TBL] [Abstract][Full Text] [Related]
42. Unrelated Cord Blood Transplantation for Acute Leukemia Diagnosed in the First Year of Life: Outcomes and Risk Factor Analysis.
Ruggeri A; Volt F; Locatelli F; Michel G; Diaz de Heredia C; Abecasis M; Zecca M; Vora A; Yakouben K; O'Brien TA; Giardino S; Cornish J; Rocha V; Peters C; Bader P; Gluckman E; Dalle JH
Biol Blood Marrow Transplant; 2017 Jan; 23(1):96-102. PubMed ID: 27777140
[TBL] [Abstract][Full Text] [Related]
43. Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT.
Nagler A; Galimard JE; Labopin M; Blaise D; Arcese W; Trisolini SM; Wu D; Pigneux A; Van Gorkom G; Rubio MT; Gedde-Dahl T; Huynh A; Lanza F; Gorin NC; Mohty M
Cancer Med; 2023 Jan; 12(2):1482-1491. PubMed ID: 35891608
[TBL] [Abstract][Full Text] [Related]
44. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.
Sanz J; Galimard JE; Labopin M; Afanasyev B; Angelucci E; Ciceri F; Blaise D; Cornelissen JJ; Meijer E; Diez-Martin JL; Koc Y; Rovira M; Castagna L; Savani B; Ruggeri A; Nagler A; Mohty M;
J Hematol Oncol; 2020 May; 13(1):46. PubMed ID: 32375860
[TBL] [Abstract][Full Text] [Related]
45. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Malard F; Labopin M; Stuhler G; Bittenbring J; Ganser A; Tischer J; Michallet M; Kröger N; Schmid C; Huynh A; Hallek M; Savani BN; Mohty M; Nagler A
Biol Blood Marrow Transplant; 2017 Feb; 23(2):278-284. PubMed ID: 27816650
[TBL] [Abstract][Full Text] [Related]
46. The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT.
Nagler A; Labopin M; Kröger N; Schroeder T; Gedde-Dahl T; Eder M; Franke GN; Blau IW; Salmenniemi U; Socie G; Schetelig J; Stelljes M; Ciceri F; Mohty M
Bone Marrow Transplant; 2023 Dec; 58(12):1339-1347. PubMed ID: 37660157
[TBL] [Abstract][Full Text] [Related]
47. Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia.
Bazarbachi A; Labopin M; Blaise D; Forcade E; Socié G; Berceanu A; Angelucci E; Bulabois CE; Kröger N; Rambaldi A; Ceballos P; Mielke S; El Cheikh J; Yakoub-Agha I; Savani B; Spyridonidis A; Nagler A; Mohty M
Bone Marrow Transplant; 2021 Mar; 56(3):622-634. PubMed ID: 33020591
[TBL] [Abstract][Full Text] [Related]
48. Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.
Ustun C; Giannotti F; Zhang MJ; Wang HL; Brunstein C; Labopin M; Rocha V; de Lima M; Baron F; Sandmaier BM; Eapen M; Gluckman E; Nagler A; Weisdorf DJ; Ruggeri A
Leukemia; 2017 Jun; 31(6):1408-1414. PubMed ID: 28119528
[TBL] [Abstract][Full Text] [Related]
49. Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study.
Al Hamed R; Ngoya M; Galimard JE; Sengeloev H; Gedde-Dahl T; Kulagin A; Platzbecker U; Yakoub-Agha I; Byrne JL; Valerius T; Socie G; Kröger N; Blaise D; Bazarbachi A; Sanz J; Ciceri F; Nagler A; Mohty M
Cancer; 2023 Sep; 129(17):2645-2654. PubMed ID: 37269074
[TBL] [Abstract][Full Text] [Related]
50. GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT.
Baron F; Labopin M; Tischer J; Raiola AM; Vydra J; Blaise D; Chiusolo P; Stölzel F; Fanin R; Chevallier P; Nagler A; Ciceri F; Mohty M
J Hematol Oncol; 2023 Feb; 16(1):10. PubMed ID: 36782226
[TBL] [Abstract][Full Text] [Related]
51. Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
Canaani J; Labopin M; Huang XJ; Ciceri F; Van Lint MT; Bruno B; Santarone S; Diez-Martin JL; Blaise D; Chiusolo P; Wu D; Mohty M; Nagler A
Br J Haematol; 2018 Nov; 183(3):411-420. PubMed ID: 30117144
[TBL] [Abstract][Full Text] [Related]
52. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
Brissot E; Labopin M; Stelljes M; Ehninger G; Schwerdtfeger R; Finke J; Kolb HJ; Ganser A; Schäfer-Eckart K; Zander AR; Bunjes D; Mielke S; Bethge WA; Milpied N; Kalhs P; Blau IW; Kröger N; Vitek A; Gramatzki M; Holler E; Schmid C; Esteve J; Mohty M; Nagler A
J Hematol Oncol; 2017 Jun; 10(1):130. PubMed ID: 28646908
[TBL] [Abstract][Full Text] [Related]
53. Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission.
Lv M; Wang Y; Chang YJ; Zhang XH; Xu LP; Jiang Q; Jiang H; Lu J; Chen H; Han W; Wang FR; Wang JZ; Chen Y; Yan CH; Zhang YY; Sun YQ; Mo XD; Zhu HH; Jia JS; Zhao T; Wang J; Liu KY; Huang XJ
Clin Cancer Res; 2019 Mar; 25(6):1737-1748. PubMed ID: 30478089
[TBL] [Abstract][Full Text] [Related]
54. Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT.
Baron F; Labopin M; Blaise D; Itälä-Remes M; Socié G; Forcade E; Yakoub-Agha I; Gorin NC; Esteve J; Nagler A; Mohty M
Bone Marrow Transplant; 2021 Feb; 56(2):461-469. PubMed ID: 32887941
[TBL] [Abstract][Full Text] [Related]
55. CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT).
Maffini E; Labopin M; Blaise D; Ciceri F; Gülbas Z; Deconinck E; Leblond V; Chevallier P; Sociè G; Araujo MC; Koc Y; Savani BN; Gorin NC; Lanza F; Nagler A; Mohty M
Am J Hematol; 2020 Aug; 95(8):892-899. PubMed ID: 32303111
[TBL] [Abstract][Full Text] [Related]
56. The impact of pre-transplant minimal residual disease on outcome of intensified myeloablative cord blood transplant for acute myeloid leukemia in first or second complete remission.
Zheng C; Zhu X; Tang B; Zhang L; Geng L; Liu H; Sun Z
Leuk Lymphoma; 2016; 57(6):1398-405. PubMed ID: 26690538
[TBL] [Abstract][Full Text] [Related]
57. Impact of mother donor, peripheral blood stem cells and measurable residual disease on outcomes after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in children with acute leukaemia.
Rocha V; Arcuri LJ; Seber A; Colturato V; Zecchin VG; Kuwahara C; Nichele S; Gouveia R; Fernandes JF; Macedo AV; Tavares R; Daudt L; De Souza MP; Darrigo-Jr LG; Villela NC; Mariano LCB; Ginani VC; Zanette A; Loth G; Gomes AA; Hamerschlak N; Flowers ME; Bonfim C;
Bone Marrow Transplant; 2021 Dec; 56(12):3042-3048. PubMed ID: 34548627
[TBL] [Abstract][Full Text] [Related]
58. Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission.
Baron F; Labopin M; Ruggeri A; Volt F; Mohty M; Blaise D; Chevallier P; Sanz J; Fegueux N; Cornelissen JJ; Rambaldi A; Savani BN; Gluckman E; Nagler A
J Intern Med; 2019 Apr; 285(4):446-454. PubMed ID: 30561052
[TBL] [Abstract][Full Text] [Related]
59. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
Aoudjhane M; Labopin M; Gorin NC; Shimoni A; Ruutu T; Kolb HJ; Frassoni F; Boiron JM; Yin JL; Finke J; Shouten H; Blaise D; Falda M; Fauser AA; Esteve J; Polge E; Slavin S; Niederwieser D; Nagler A; Rocha V;
Leukemia; 2005 Dec; 19(12):2304-12. PubMed ID: 16193083
[TBL] [Abstract][Full Text] [Related]
60. Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Maffini E; Ngoya M; Galimard JE; Harbi S; Kröger N; Platzbecker U; Sengeloev H; Craddock C; Potter V; Choi G; Chevallier P; Stölzel F; Tholouli E; Maertens J; Ciceri F; Cornelissen J; Sanz J; Spyridonidis A; Lanza F; Nagler A; Mohty M
Bone Marrow Transplant; 2023 Sep; 58(9):1033-1041. PubMed ID: 37386253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
